Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.
Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
Gynecol Oncol. 2021 Jun;161(3):795-801. doi: 10.1016/j.ygyno.2021.03.029. Epub 2021 Mar 31.
Deficient expression of mismatch repair proteins (MMR) has been suggested to be a predictor of resistance of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) to conservative treatment.
To assess the predictive value of MMR immunohistochemistry in patients conservatively treated for AEH and EEC, and to calculate its predictive accuracy.
All patients with AEH or EEC conservatively treated with hysteroscopic resection plus progestins in two referral centers from January 2004 to July 2019 were retrospectively assessed. Immunohistochemistry for MMR was ad hoc performed. Study outcomes were: (i) the association of a deficient immunohistochemical expression of MMR with resistance and recurrence of AEH and EEC after conservative treatment, and (ii) the accuracy of MMR immunohistochemistry in predicting the outcome of conservative treatment. Relative risk (RR) for the associations, and sensitivity, specificity and area under the curve (AUC) on receiver operating characteristic curve for the predictive accuracy were calculated.
Sixty-nine women, (47 AEH and 22 EEC) were included; deficient MMR expression was observed in 8.7% of cases. Resistance to conservative treatment was more common in MMR-deficient than MMR-proficient cases (33.3% vs 15.9%; RR = 2.1), but with no statistical significance (p = 0.2508). On the other hand, recurrence was significantly more common in MMR-deficient than MMR-proficient cases (100% vs 26.4%; RR = 3.8; p < 0.0001). In predicting recurrence, a deficient immunohistochemical expression of MMR showed sensitivity = 22.2%, specificity = 100%, and AUC = 0.61.
Deficient MMR immunohistochemical expression does not imply resistance of AEH/EEC to conservative treatment. On the other hand, MMR-deficiency appears as a highly specific predictor of recurrence of AEH/EEC after initial regression.
错配修复蛋白(MMR)表达缺陷被认为是预测非典型子宫内膜增生(AEH)和早期子宫内膜癌(EEC)对保守治疗的耐药性的指标。
评估 MMR 免疫组化在接受宫腔镜切除加孕激素保守治疗的 AEH 和 EEC 患者中的预测价值,并计算其预测准确性。
回顾性分析 2004 年 1 月至 2019 年 7 月在两个转诊中心接受宫腔镜切除加孕激素保守治疗的所有 AEH 或 EEC 患者。行 MMR 免疫组化检查。研究结果为:(i)MMR 免疫组化表达缺陷与保守治疗后 AEH 和 EEC 耐药和复发的相关性;(ii)MMR 免疫组化预测保守治疗结局的准确性。计算相对风险(RR)、敏感性、特异性和受试者工作特征曲线(ROC)下面积(AUC)。
共纳入 69 例患者(47 例 AEH 和 22 例 EEC),其中 8.7%存在 MMR 表达缺陷。MMR 缺陷组保守治疗耐药的发生率高于 MMR 正常组(33.3% vs 15.9%;RR = 2.1),但差异无统计学意义(p = 0.2508)。另一方面,MMR 缺陷组的复发率明显高于 MMR 正常组(100% vs 26.4%;RR = 3.8;p < 0.0001)。在预测复发方面,MMR 免疫组化表达缺陷的敏感性为 22.2%,特异性为 100%,AUC 为 0.61。
MMR 免疫组化表达缺陷并不意味着 AEH/EEC 对保守治疗的耐药性。另一方面,MMR 缺陷似乎是 AEH/EEC 初始消退后复发的高度特异性预测指标。